BR112014023795A8 - Uso de inibidores de ccr3 - Google Patents
Uso de inibidores de ccr3Info
- Publication number
- BR112014023795A8 BR112014023795A8 BR112014023795A BR112014023795A BR112014023795A8 BR 112014023795 A8 BR112014023795 A8 BR 112014023795A8 BR 112014023795 A BR112014023795 A BR 112014023795A BR 112014023795 A BR112014023795 A BR 112014023795A BR 112014023795 A8 BR112014023795 A8 BR 112014023795A8
- Authority
- BR
- Brazil
- Prior art keywords
- eosinophilic
- alkyl
- ccr3 inhibitors
- macular degeneration
- related macular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Structure Of Transmissions (AREA)
Abstract
USO DE INIBIDORES DE CCR3. A presente invenção refere-se aos inibidores de CCR3 da fórmula (1), em que R1 é H, C1-6-alquila, C0-4-alquil-C3-6-cicloalquila, C1-6-haloalquila; R2 é H, C1-6-alquila; X é um ânion selecionado do grupo que consiste em cloreto ou 1/2 dibenzoiltartrato; j é 1 ou 2, para o uso como um medicamento para o tratamento de doenças selecionadas dentre degeneração macular seca relacionada à idade (dAMD), degeneração macular molhada relacionada à idade (wAMD), retinopatia da prematuridade (ROP), oclusão da veia retiniana central (CRVO), polipose nasal, esofagite eosinofílica, gastroenterite eosinofílica (por exemplo gastrite eosinofílica e ententerite eosinofílica), síndrome hiperreosinofílica e síndrome de Churg Strauss.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937.2 | 2012-04-03 | ||
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014023795A2 BR112014023795A2 (pt) | 2017-06-20 |
| BR112014023795A8 true BR112014023795A8 (pt) | 2017-10-10 |
| BR112014023795B1 BR112014023795B1 (pt) | 2021-09-08 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014023795-6A BR112014023795B1 (pt) | 2012-04-03 | 2013-04-02 | Uso de inibidores de ccr3 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (pt) |
| EP (3) | EP3763369B1 (pt) |
| JP (2) | JP2015512432A (pt) |
| KR (4) | KR20140144200A (pt) |
| CN (2) | CN110384699A (pt) |
| AU (1) | AU2013245027B2 (pt) |
| BR (1) | BR112014023795B1 (pt) |
| CA (1) | CA2869269C (pt) |
| CL (1) | CL2014002523A1 (pt) |
| CY (1) | CY1123222T1 (pt) |
| DK (1) | DK2833884T3 (pt) |
| EA (1) | EA032263B1 (pt) |
| ES (1) | ES2811554T3 (pt) |
| HR (1) | HRP20201165T1 (pt) |
| HU (1) | HUE051648T2 (pt) |
| IL (1) | IL234262A (pt) |
| IN (1) | IN2014DN06989A (pt) |
| LT (1) | LT2833884T (pt) |
| MX (1) | MX2014011786A (pt) |
| NZ (1) | NZ628882A (pt) |
| PH (1) | PH12014502239A1 (pt) |
| PL (1) | PL2833884T3 (pt) |
| PT (1) | PT2833884T (pt) |
| RS (1) | RS60665B1 (pt) |
| SI (1) | SI2833884T1 (pt) |
| WO (1) | WO2013149986A1 (pt) |
| ZA (1) | ZA201406082B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| US11045284B2 (en) | 2016-11-24 | 2021-06-29 | Kirishima Seiko Co., Ltd. | Dental brace and method for attaching dental brace |
| MX2019012012A (es) * | 2017-04-05 | 2019-12-11 | Alkahest Inc | Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3. |
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| AU2018347447B2 (en) * | 2017-10-13 | 2024-03-07 | Alkahest, Inc. | Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors |
| SG11202010115RA (en) | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
| CN112789044A (zh) * | 2018-09-26 | 2021-05-11 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| JP2023529719A (ja) * | 2020-06-11 | 2023-07-11 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患の転帰改善方法 |
| US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| US7323311B2 (en) * | 2000-03-03 | 2008-01-29 | Cambridge Antibody Technology Limited | Methods of obtaining a specific binding member that binds eotaxin |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010138591A1 (en) * | 2009-05-26 | 2010-12-02 | University Of Kentucky Research Foundation | Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en active Application Filing
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko active Application Filing
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko active Application Filing
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active IP Right Cessation
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Application Discontinuation
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-07-27 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014023795A8 (pt) | Uso de inibidores de ccr3 | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| ECSP089020A (es) | Compuestos novedosos como ligandos del receptor de canabinoides y usos de los mismos | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112015022462A2 (pt) | inibidores de ido | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| BR112014022106A2 (pt) | derivados macrocíclicos para o tratamento de doenças | |
| BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
| BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| BR112015021999A2 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido) | |
| EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
| BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
| UY34996A (es) | Agente de control de endoparásitos | |
| BR112015029090A2 (pt) | compostos de 3,4-di-hidroisoquinolin-2(1h)-ila | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| BRPI0911679B8 (pt) | composto aciltioureia ou um sal do mesmo, uso do dito composto para tratar câncer, bem como agente farmacêutico, agente antitumoral e composição farmacêutica compreendendo dito composto | |
| BR112018074961A2 (pt) | derivados de nucleosídeo de fosforamidato como agentes anticâncer | |
| BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ALKAHEST, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2013, OBSERVADAS AS CONDICOES LEGAIS. |